Agile Therapeutics Updates Second Quarter 2022 Guidance
July 12, 2022 08:05 ET
|
Agile Therapeutics, Inc.
Twirla® Demand Guidance (Total Cycles) Expected to be at Midpoint of Guided Range Operating Expenses (OPEX) Expected to be Below Guided Range PRINCETON, N.J., July 12, 2022 (GLOBE NEWSWIRE) --...
Agile Therapeutics to Participate in Maxim Group’s Upcoming Women’s Health Panel
July 08, 2022 08:05 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., July 08, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairman and CEO Al Altomari will be participating in a...
Agile Therapeutics Announces Closing of $24 Million Upsized Public Offering
July 06, 2022 17:16 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., July 06, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced the closing of its...
Agile Therapeutics Announces Pricing of $24 Million Upsized Public Offering
July 01, 2022 09:20 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., July 01, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced the pricing of its...
Agile Therapeutics to Present at The H.C. Wainwright Global Investment Conference
May 17, 2022 08:01 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., May 17, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced that Al Altomari, Chairman and Chief Executive Officer, will...
Agile Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 12, 2022 16:05 ET
|
Agile Therapeutics, Inc.
Twirla Experienced Another Quarter of Double-Digit Demand Growth in First Quarter 2022 Twirla Business Plan Progressing Company Anticipates Future 2022 Quarterly Operating Expenses to be Lower ...
Agile Therapeutics Announces Findings of First-Year Post-Marketing Pharmacovigilance in ACOG Poster Presentation
May 05, 2022 17:01 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today publicly released the findings of its first year of post-marketing...
Agile Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on Thursday, May 12, 2022
May 03, 2022 07:30 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., May 03, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report first quarter 2022 financial results after the...
Agile Therapeutics Announces 1-For-40 Reverse Stock Split
April 26, 2022 08:00 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile”), a women's healthcare company, today announced that the Board approved a 1-for-40 reverse stock...
Agile Therapeutics Announces First Quarter 2022 Prescription Data for Twirla®
April 14, 2022 07:30 ET
|
Agile Therapeutics, Inc.
29% increase in Twirla cycles27% increase in total prescriptions (TRx) of Twirla PRINCETON, N.J., April 14, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare...